Santen and UBE announced the FDA approval of Omlonti for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.
The FDA granted the approval on Sept. 22, according to the agency’s website.
Omlonti (omidenepag isopropyl ophthalmic solution 0.002%) was jointly developed by Santen and UBE, according to a press release from Santen. The active ingredient, omidenepag isopropyl, which was developed by UBE, is a relatively selective prostaglandin EP2 receptor agonist that increases aqueous humor drainage through the trabecular and uveoscleral outflow